<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00435981</url>
  </required_header>
  <id_info>
    <org_study_id>D/P2/04/3</org_study_id>
    <secondary_id>EUDRACT 2004-003764-30</secondary_id>
    <nct_id>NCT00435981</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Diamyd® in Children and Adolescents With Type 1 Diabetes</brief_title>
  <official_title>A Phase II, Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Investigate the Impact of Diamyd® on the Progression of Diabetes in Patients Newly Diagnosed With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diamyd Therapeutics AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Diamyd Therapeutics AB</source>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled phase II study to investigate if a prime and boost
      of 20ug Diamyd® (rhGAD65 formulated in Alhydrogel®), administered subcutaneously four weeks
      apart, is safe and can preserve beta cell function in children and adolescents with type 1
      diabetes with a diabetes duration less than 18 months at intervention.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the efficacy of Diamyd® 20ug versus placebo with respect to preserving residual insulin secretion as measured by C-peptide levels. The effect of intervention will be evaluated at month 15 (main study period) and at month 30 (Extension phase).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of Diamyd® 20ug.</measure>
  </secondary_outcome>
  <enrollment>70</enrollment>
  <condition>Type 1 Diabetes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhGAD65 formulated in Alhydrogel® (Diamyd®)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Male and female patients between 10 and 18 years of age, diagnosed with type 1
             diabetes within 18 months

          -  Fasting C-peptide level above 0.1 nmol/l

          -  Presence of GAD65 antibodies

          -  Written informed consent (patient and parent/guardian)

        Key Exclusion Criteria:

          -  Secondary diabetes mellitus or MODY

          -  Treatment with immunosuppressants

          -  Treatment with any vaccine within 1 month prior to first Diamyd® dose or planned
             treatment with vaccine up to 2 months after the second Diamyd® dose

          -  Participation in other clinical trials with a new chemical entity within the previous
             3 months

          -  History of certain diseases or conditions (e.g. epilepsy, anaemia, alcohole or drug
             abuse)

          -  HIV or hepatitis

          -  Presence of associated serious disease or condition which in the opinion of the
             investigator makes the patient non-eligible for the study

          -  Pregnancy (or planned pregnancy within one year after 2nd administration)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnny Ludvigsson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Div of Pediatrics, Dept of Clinical and Molecular Medicine, Faculty of Health Sciences, Linkoping University, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Borås Hospital</name>
      <address>
        <city>Borås</city>
        <zip>SE-501 82</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Queen Silvia Children´s Hospital</name>
      <address>
        <city>Göteborg</city>
        <zip>SE-416 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Halmstad Hospital</name>
      <address>
        <city>Halmstad</city>
        <zip>SE-301 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ryhov Hospital</name>
      <address>
        <city>Jönköping</city>
        <zip>SE-551 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linköping University</name>
      <address>
        <city>Linköping</city>
        <zip>SE-581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, MAS</name>
      <address>
        <city>Malmö</city>
        <zip>SE-205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Astrid Lindgren Children´s Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <zip>SE-701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2007</study_first_submitted>
  <study_first_submitted_qc>February 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2007</study_first_posted>
  <last_update_submitted>January 29, 2008</last_update_submitted>
  <last_update_submitted_qc>January 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2008</last_update_posted>
  <keyword>Type 1 diabetes</keyword>
  <keyword>GAD65</keyword>
  <keyword>Autoimmunity</keyword>
  <keyword>C-peptide</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aluminum Hydroxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

